ReviewFrontiers in immunology2021
mRNA Vaccine: How to Meet the Challenge of SARS-CoV-2.
Review in Frontiers in immunology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 23 citations in OpenAlex.
- Article
- An mRNA vaccine confers enhanced protection against herpes simplex virus through an IFN-I-dependent pathway.NPJ vaccines · 2026Article
- Designing a novel multiepitope vaccine candidate against Treponema pallidum via adhesins using reverse vaccinology.Scientific reports · 2026Article
- Emotions, preventive measures, and risk perception in post-emergency COVID-19: a cross-sectional study in Italian university staff during the seasonal vaccination campaign.BMC public health · 2026Article
- Development of a novel multi-epitope vaccine against Ureaplasma urealyticum infection through reverse vaccinology approach.Molecular diversity · 2026Article
- Development of a Safe and Effective mRNA Candidate Vaccine Against PEDV G2c Genotype Infection.Viruses · 2025Article
- High-throughput multiplexed gene and cell doping analysis through CRISPR-Cas12a system integrated with blood direct PCR.Science advances · 2025Article
- Coinfection ofFrontiers in cellular and infection microbiology · 2025Article
- Review
- Advancements in the development of nucleic acid vaccines for syphilis prevention and control.Human vaccines & immunotherapeutics · 2023Review
- Machine Learning Classification of Time since BNT162b2 COVID-19 Vaccination Based on Array-Measured Antibody Activity.Life (Basel, Switzerland) · 2023Article
- Novel receptor, mutation, vaccine, and establishment of coping mode for SARS-CoV-2: current status and future.Frontiers in microbiology · 2023Review
- Development and evaluation of an inactivated coxsackievirus A16 vaccine in gerbils.Emerging microbes & infections · 2022Article
- Optimized intramuscular immunization with VSV-vectored spike protein triggers a superior immune response to SARS-CoV-2.NPJ vaccines · 2022Article
- Article
- COVID-19 vaccination coverage by company size and the effects of workplace vaccination program in Japan: a cohort study.Environmental health and preventive medicine · 2022Article
- Glutathione deficiency in the pathogenesis of SARS-CoV-2 infection and its effects upon the host immune response in severe COVID-19 disease.Frontiers in microbiology · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) with high infectivity, pathogenicity, and variability, is a global pandemic that severely affected public health and the world economy. The development of safe and effective vaccines is crucial to the prevention and control of an epidemic. As an emerging technology, mRNA vaccine is widely used for infectious disease prevention and control and has significant safety, efficacy, and high production. It has received support and funding from many pharmaceutical enterprises and becomes one of the main technologies for preventing COVID-19. This review introduces the current status of SARS-CoV-2 vaccines, specifically mRNA vaccines, focusing on the challenges of developing mRNA vaccines against SARS-CoV-2, and discusses the relevant strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.